JPH08511006A - 安定な銅（▲ｉ▼）錯体及びそれに関する方法 - Google Patents

安定な銅（▲ｉ▼）錯体及びそれに関する方法

Info

Publication number
JPH08511006A
JPH08511006A JP7501073A JP50107395A JPH08511006A JP H08511006 A JPH08511006 A JP H08511006A JP 7501073 A JP7501073 A JP 7501073A JP 50107395 A JP50107395 A JP 50107395A JP H08511006 A JPH08511006 A JP H08511006A
Authority
JP
Japan
Prior art keywords
copper
complex
complexes
stable
stable copper
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP7501073A
Other languages
English (en)
Japanese (ja)
Inventor
ジェイ． パレンバーグ，アレクサンダー
ブランカ，アンドリュー
エム． マーシュナー，トーマス
エム． パット，レオナード
Original Assignee
プロサイト コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロサイト コーポレイション filed Critical プロサイト コーポレイション
Publication of JPH08511006A publication Critical patent/JPH08511006A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP7501073A 1993-06-02 1994-06-02 安定な銅（▲ｉ▼）錯体及びそれに関する方法 Pending JPH08511006A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7144093A 1993-06-02 1993-06-02
US08/071,440 1993-06-02
PCT/US1994/006247 WO1994027594A2 (en) 1993-06-02 1994-06-02 Stable copper(i) complexes and methods related thereto

Publications (1)

Publication Number Publication Date
JPH08511006A true JPH08511006A (ja) 1996-11-19

Family

ID=22101339

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7501073A Pending JPH08511006A (ja) 1993-06-02 1994-06-02 安定な銅（▲ｉ▼）錯体及びそれに関する方法

Country Status (8)

Country Link
EP (1) EP0701439A1 (enrdf_load_stackoverflow)
JP (1) JPH08511006A (enrdf_load_stackoverflow)
AU (1) AU7051794A (enrdf_load_stackoverflow)
CA (1) CA2163640A1 (enrdf_load_stackoverflow)
OA (1) OA10198A (enrdf_load_stackoverflow)
TW (1) TW239077B (enrdf_load_stackoverflow)
WO (1) WO1994027594A2 (enrdf_load_stackoverflow)
ZA (1) ZA943857B (enrdf_load_stackoverflow)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543885A (ja) * 2005-06-20 2008-12-04 ダイナミクリア ピーティーワイ リミテッド 皮膚病変治療用組成物
JP2014129346A (ja) * 2012-12-28 2014-07-10 Hung-Chien Chien 組み換えタンパク質、当該組み換えタンパク質を含む医薬組成物、及び前記組み換えタンパク質の製造方法
JP2014231525A (ja) * 2008-09-03 2014-12-11 株式会社Ｎｂｃメッシュテック 抗ウイルス剤
JP2021532066A (ja) * 2018-06-04 2021-11-25 ケミストリーアールエックス.Chemistryrx. 発毛を刺激するための局所的組成物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562854B2 (en) 1994-12-14 2003-05-13 Axys Pharmaceuticals, Inc. Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders
WO1996039144A1 (en) * 1995-06-06 1996-12-12 Procyte Corporation Stable copper(i) complexes as active therapeutic substances
US5637311A (en) * 1995-06-29 1997-06-10 Procyte Corporation Zinc(II) complexes and methods related thereto
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
US6150379A (en) * 1997-11-26 2000-11-21 Axys Pharmaceuticals, Inc. Compounds and compositions as anticoagulants
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
US8829051B2 (en) * 2004-05-24 2014-09-09 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
WO2019055490A1 (en) 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University PACKAGING OF IRRADIED FABRIC FOR FAT GREETING RETENTION

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760051A (en) * 1985-01-24 1988-07-26 Pickart Loren R Use of GHL-Cu as a wound-healing and anti-inflammatory agent
JPS6259213A (ja) * 1985-09-10 1987-03-14 Eisai Co Ltd ス−パ−オキサイド除去剤

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543885A (ja) * 2005-06-20 2008-12-04 ダイナミクリア ピーティーワイ リミテッド 皮膚病変治療用組成物
JP2014231525A (ja) * 2008-09-03 2014-12-11 株式会社Ｎｂｃメッシュテック 抗ウイルス剤
JP2014129346A (ja) * 2012-12-28 2014-07-10 Hung-Chien Chien 組み換えタンパク質、当該組み換えタンパク質を含む医薬組成物、及び前記組み換えタンパク質の製造方法
JP2021532066A (ja) * 2018-06-04 2021-11-25 ケミストリーアールエックス.Chemistryrx. 発毛を刺激するための局所的組成物

Also Published As

Publication number Publication date
CA2163640A1 (en) 1994-12-08
ZA943857B (en) 1995-02-01
EP0701439A1 (en) 1996-03-20
OA10198A (en) 1996-12-18
WO1994027594A2 (en) 1994-12-08
WO1994027594A3 (en) 1995-04-27
TW239077B (enrdf_load_stackoverflow) 1995-01-21
AU7051794A (en) 1994-12-20

Similar Documents

Publication Publication Date Title
Kimura et al. Increases in cyclic GMP levels in brain and liver with sodium azide an activator of guanylate cyclase
Qian et al. Structure and function of HECT E3 ubiquitin ligases and their role in oxidative stress
Iqubal et al. Nerolidol attenuates cyclophosphamide-induced cardiac inflammation, apoptosis and fibrosis in Swiss Albino mice
Lirk et al. Inducible nitric oxide synthase-time for reappraisal
Marko et al. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells
Noiri et al. Oxidative and nitrosative stress in acute renal ischemia
Frei On the role of vitamin C and other antioxidants in atherogenesis and vascular dysfunction
JPH08511006A (ja) 安定な銅（▲ｉ▼）錯体及びそれに関する方法
Mariappan et al. TNF-induced mitochondrial damage: a link between mitochondrial complex I activity and left ventricular dysfunction
Crutchley et al. Stimulation of fibrinolytic activity in human skin fibroblasts by prostaglandins E1, E2 and I2.
EP1231914B1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
JP2009242438A (ja) ノルジヒドログアヤレティク酸誘導体を使用して腫瘍を処置するための方法
Wang et al. Wheat germ-derived peptide ADWGGPLPH abolishes high glucose-induced oxidative stress via modulation of the PKCζ/AMPK/NOX4 pathway
WO1996039144A1 (en) Stable copper(i) complexes as active therapeutic substances
Rosowsky et al. Methotrexate analogs. 19. Replacement of the glutamate side-chain in classical antifolates by L-homocysteic acid and L-cysteic acid: effect on enzyme inhibition and antitumor activity
Kosonen et al. Inhibition by nitric oxide-releasing compounds of prostacyclin production in human endothelial cells
Faaland et al. Rapid uptake of tyrphostin into A431 human epidermoid cells is followed by delayed inhibition of epidermal growth factor (EGF)-stimulated EGF receptor tyrosine kinase activity
EP0752872B1 (en) Nadh oxidase as a target in diagnosis and therapy
Diebold et al. Influences of lovastatin administration on the respiratory burst of leukocytes and the phosphorylation potential of mitochondria in guinea pigs
Chida et al. Activation of Protein Kinase C and Specific Phosphorylation of a M r 90,000 Membrane Protein of Promotable BALB/3T3 and C3H/10T½ Cells by Tumor Promoters
US20020022022A1 (en) Inhibition of cell proliferation and matrix synthesis by antioxidants and NAD(P)H oxidase inhibitors
Woods et al. The role of glutathione in chronic adaptation to oxidative stress: studies in a normal rat kidney epithelial (NRK52E) cell model of sustained upregulation of glutathione biosynthesis
WO1997001559A1 (en) Zinc(ii) complexes and methods related thereto
Sánchez-Gómez et al. Modulation of GSTP1-1 oligomerization by electrophilic inflammatory mediators and reactive drugs
De La Rosa et al. Changes in the relative amount of subunits of methionine adenosyltransferase in human lymphocytes upon stimulation with a polyclonal T cell mitogen.